Logotype for Ouro Fino Saúde Animal Participações SA

Ouro Fino Saúde Animal Participações (OFSA3) Q2 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Ouro Fino Saúde Animal Participações SA

Q2 2024 earnings summary

1 Sep, 2026

Executive summary

  • Revenue excluding Foot-and-Mouth Disease (FMD) vaccine grew 7.3% in 2Q24 and 7.0% in 6M24, driven by strong performance in production and companion animal segments despite challenging market conditions and the FMD vaccination campaign's cancellation in Brazil.

  • Launched innovative products, including Ferappease for cattle and pigs, and approved two new swine vaccines for launch in the second half of 2024.

  • Profitability improved with gross margin, EBITDA margin, and net margin all expanding, supported by efficiency gains and cost discipline.

  • International operations faced revenue declines, mainly due to FMD vaccine discontinuation and challenging conditions in Mexico, though Colombia performed well.

  • No significant economic impact from Rio Grande do Sul floods on business operations.

Financial highlights

  • Net revenue for Q2 2024 was R$231 million (BRL), with R$27 million from FMD; adjusted revenue grew 7.3% YoY, and gross margin improved to 48.2% in Q2 2024 and 51.2% YTD ex-FMD.

  • Adjusted EBITDA for 6M24 rose 51.3% YoY to R$57.0 million, with margin up 5.0 p.p.; net income for H1 2024 reached R$29.7 million, reversing a prior-year loss.

  • Operating cash flow generation was R$100 million in 6M24, and cash and equivalents increased to R$343.2 million as of June 2024.

  • Net debt reduced by 47.3% YoY to R$67.5 million, with leverage dropping to 0.4x EBITDA.

  • SG&A expenses remained flat or declined YoY, reflecting ongoing cost discipline.

Outlook and guidance

  • Confident in meeting commercial and financial targets for the year, with expectations of further margin and revenue growth as new products are launched and plant capacity is optimized.

  • Two new vaccines for the pig market approved and scheduled for launch in the second semester.

  • Continued focus on cost control, innovation, and international expansion, particularly in Latin America.

  • No significant operational impacts identified from the Rio Grande do Sul climate event as of the report date.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more